sellWeak cluster of 210b5-1 plan
Sharon Mates sold $5.1M of ITCI
Chairman and CEO at Intra-Cellular Therapies, Inc.. 70,000 shares at an average of $72.70, traded Aug 29, 2024, filed Aug 30, 2024.
Warning score
23Value
$5.1M
70,000 shares
Holdings after
1,070,329
-6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$5.1M at market
- 0Share of holdings soldSold 6.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-102475, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 29, 2024 | MOption exercise Common Stock10b5-1 | +35,604 | $12.73 | $453k | 1,105,933 | Aug 30, 2024 |
| Aug 29, 2024 | SOpen-market sale Common Stock10b5-1 | -29,832 | $72.44 | $2.2M | 1,076,101 | Aug 30, 2024 |
| Aug 29, 2024 | SOpen-market sale Common Stock10b5-1 | -5,772 | $73.25 | $423k | 1,070,329 | Aug 30, 2024 |
| Aug 30, 2024 | MOption exercise Common Stock10b5-1 | +34,396 | $12.73 | $438k | 1,104,725 | Aug 30, 2024 |
| Aug 30, 2024 | SOpen-market sale Common Stock10b5-1 | -28,203 | $72.73 | $2.1M | 1,076,522 | Aug 30, 2024 |
| Aug 30, 2024 | SOpen-market sale Common Stock10b5-1 | -6,193 | $73.32 | $454k | 1,070,329 | Aug 30, 2024 |
| Aug 29, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -35,604 | $0.00 | $0 | 137,093 | Aug 30, 2024 |
| Aug 30, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -34,396 | $0.00 | $0 | 102,697 | Aug 30, 2024 |
Related signals
Other insiders at Intra-Cellular Therapies, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $8.7M 102,697 shares | -9% | |
| 30Weak | Intra-Cellular Therapies, Inc. | Michael Halstead President | $3.7M 41,583 shares | -182% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $7.1M 95,925 shares | -9% | |
| 28Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $9.1M 121,073 shares | -11% | |
| 43Moderate | Intra-Cellular Therapies, Inc. | Mark Neumann EVP, Chief Commercial Officer | $1.4M 18,714 shares | -39% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Rory B Riggs director | $337k 4,462 shares | -4% | |
| 33Weak | Intra-Cellular Therapies, Inc. | Robert L Van Nostrand director | $1.5M 20,000 shares | -67% | |
| 25Weak | Intra-Cellular Therapies, Inc. | Suresh K. Durgam EVP, Chief Medical Officer | $673k 10,162 shares | -45% | |
| 40Moderate | Intra-Cellular Therapies, Inc. | Michael Halstead EVP and General Counsel | $1.4M 20,477 shares | -156% | |
| 47Moderate | Intra-Cellular Therapies, Inc. | Lawrence J. Hineline SVP of Finance, CFO | $1.5M 23,253 shares | -177% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.